Morgan Stanley Initiates Organogenesis(ORGO.US) With Hold Rating, Announces Target Price $4
Morgan Stanley Sticks to Their Hold Rating for Organogenesis Holdings (ORGO)
Cantor Fitzgerald Maintains Organogenesis(ORGO.US) With Buy Rating, Raises Target Price to $3.8
Lake Street Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $5
BTIG Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $6
Lake Street Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $5
Lake Street Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $5
Organogenesis Holdings (ORGO) Receives a Buy From Lake Street
Cantor Fitzgerald Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $3.5
Organogenesis Holdings (ORGO) Receives a Buy From Cantor Fitzgerald
Lake Street Initiates Coverage On Organogenesis Hldgs With Buy Rating, Announces Price Target of $5
Organogenesis Hldgs Analyst Ratings
Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating
Buy Rating Affirmed for Organogenesis Holdings Amid Stable Product Pricing and Positive Market Dynamics
Cantor Fitzgerald Reiterates Overweight on Organogenesis Hldgs, Maintains $5 Price Target
Organogenesis Hldgs Analyst Ratings
Organogenesis Holdings: A Buy Rating With Anticipated Turnaround and Growth Prospects
Cantor Fitzgerald Initiates Coverage On Organogenesis Hldgs With Overweight Rating, Announces Price Target of $5
Organogenesis Hldgs Analyst Ratings
BTIG Maintains Buy on Organogenesis Hldgs, Raises Price Target to $6
No Data